ArticleJACC. Asia2026

Trial-Eligible vs Trial-Ineligible Low-Risk Patients Undergoing TAVR: Insights From the LAPLACE-TAVI Registry.

Hanyi Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.